First US injectable BPC-157 RCT, anyone got details

This is the thing I've wanted for four years. My whole spreadsheet is n=1 self report, would be nice to have an actual control arm to compare against instead of me guessing whether week 6 improvement was the peptide or just time and loading.

Worth being clear about what this actually changes. A registered RCT means someone got IRB approval and is running it under an IND, which is a real step up from the animal literature we've all been leaning on. But even a well designed trial takes years, you've got enrollment, the actual run, then data analysis and publication, then whatever regulatory conversation follows if results are positive. It does not mean injectable BPC-157 becomes broadly prescribable or insurance covered anytime soon, and it does not undo where things currently stand with compounding access in the US. Think of this as the first domino, not the outcome.

Finally, some real human data coming.

What's the injury population, tendon specific or general?

Nobody's posted the actual protocol details publicly yet as far as I can find, just that it's tissue healing broadly. I'd want to know injury type, injection frequency, duration, and whether they're doing imaging or just patient reported outcomes before I get excited about the design. Plenty of RCTs get registered and never finish enrollment.

Hoping this means better access eventually, been chasing this stuff for two years now.

Access won't fix your loading program though.

From the pharmacy side, the compounding restrictions are the real bottleneck right now, not lack of research interest. A trial doesn't change scheduling status.

Good thread. Reminder we're discussing the trial's existence and design here, not sourcing questions, keep it in this lane and we're fine.